. . . "On Friday, the FDA's Anti-Infective Drugs Advisory Committee will discuss the use of miltefosine capsules to treat visceral (involving internal organs), mucosal (involving areas such as inside the mouth and nose), and cutaneous (involving the skin) leishmaniasis, an infection caused by a parasite." . .